Search clinical trials for: Extended Release

Total 5392 results

Institut National de la Santé Et de la Recherche...

Completed

Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN) (DEPARRESTCLIN)

Major Depressive Disorder | Major Depressive Episode

France
Yale University
University of South Florida; New York University; Icahn School of Medicine at... and other collaborators

Completed

Guanfacine in Children With Tic Disorders

Tourette Syndrome | Tourette Disorder

United States
Ironshore Pharmaceuticals and Development, Inc

Completed

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD (HLD100-103)

Attention-Deficit Hyperactivity Disorder (ADHD)

United States
Durect

Completed

Trial of Extended Release Bupivacaine for Pain Relief After Surgery (PERSIST)

Post Operative Pain

United States
Supernus Pharmaceuticals, Inc.

Completed

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD

ADHD

United States
Supernus Pharmaceuticals, Inc.

Completed

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD

ADHD

United States
Supernus Pharmaceuticals, Inc.

Completed

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD

ADHD

United States
Shire

Completed

Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Spain, United States, Germany, Poland, Italy, Ukraine, Romania, United Kingdom, Sweden, Austria, Canada, France, Ireland
Boston University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Alcohol Disorder hOsPital Treatment Trial (ADOPT)

Alcohol Dependence | Alcohol Use Disorder | Heavy Drinking

United States
Shire

Completed

Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

Attention-Deficit/Hyperactivity Disorder

United States
NYU Langone Health
National Institute on Drug Abuse (NIDA); University of California, Los Angeles and other collaborators

Completed

Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry (XOR)

Opioid-Related Disorders | Heroin Dependence

United States
Supernus Pharmaceuticals, Inc.

Completed

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

ADHD

United States
Shire

Completed

Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe

Attention Deficit Hyperactivity Disorder (ADHD)

Spain, Germany, Ukraine, France, Italy, Austria, Belgium, Ireland, Netherlands, Poland, Romania, Sweden, United Kingdom
Shire

Completed

Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers

Healthy

United States
Shire

Completed

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

Attention-deficit/Hyperactivity Disorder

Spain, Belgium, United States, Netherlands, United Kingdom, Italy, Germany, Canada, France, Sweden
Shire

Completed

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

Colitis, Ulcerative

United States
Shire

Completed

Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

Belgium
Shire

Completed

Prevention of Recurrence of Diverticulitis (PREVENT2)

Diverticulitis

United States, Italy, Germany, Canada, Brazil, Romania, Netherlands, Finland, South Africa, Hungary
Shire

Completed

Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476

Colitis, Ulcerative

Belgium
Shire

Completed

SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

Phobia, Social | Anxiety, Separation | Generalized Anxiety Disorder (GAD)

United States
Shire

Completed

Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

Attention-Deficit/Hyperactivity Disorder

United States, Canada
Anders Fink-Jensen, MD, DMSci
The Novavì outpatient clinics, Copenhagen; Neurobiology Research Unit, Rigshospitalet... and other collaborators

Completed

Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence? (EXALT)

Addiction, Alcohol | Alcohol Dependence, in Remission

Denmark
OPKO Health, Inc.

Completed

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico, Romania, Poland, Mexico, Greece
Pfizer

Completed

BIOEQUIVALENCE STUDY IN HEALTHY PARTICIPANTS COMPARING 4 MG AND 8 MG FESOTERODINE EXTENDED-RELEASE TABLETS (TOVIAZ™), MANUFACTURED AT ZWICKAU VERSUS FREIBURG

Neurogenic Detrusor Overactivity

Belgium
Laboratorios Silanes S.A. de C.V.
Instituto Mexicano del Seguro Social

Completed

BIOAVAILABILITY OF GLI/METXR (4/850 mg) (GLMT12-SIL)

Healthy

Mexico
Laboratorios Silanes S.A. de C.V.
Instituto Mexicano del Seguro Social

Completed

BIOAVAILABILITY OF Glimepiride/Extended Release Metformin (GLI/METXR): High Fat Diet Study (GLMT13)

Healthy

Mexico
Genuine Research Center, Egypt
Hikma Pharmaceuticals LLC

Completed

Bioequivalence Study of Budesonide From Ekmasonid 9 mg Extended Release FCT (Hikma Pharma, Egypt) Versus Uceris 9 mg Extended Release Tablets (Man. for: Salix Pharm., a Division of Valeant Pharm. LLC, USA, by: Cosmo S.P.A., Italy by License of Cosmo Tech. Ltd., Ireland, Product of France)

Healthy

Egypt
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Effects of Niacin Therapy on Lipoprotein Composition and Function

Cardiovascular Disease

United States
University of Minnesota

Completed

Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients

Kidney Transplant Failure and Rejection

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder (MJ-ADHD)

Attention-deficit/Hyperactivity Disorder | Cannabis Use Disorder

United States
Cingulate Therapeutics

Completed

CTx-1301 Comparative Bioavailability Study

ADHD

United States
University of South Florida
National Cancer Institute (NCI)

Completed

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

Breast Cancer | Cardiac Toxicity

United States
University of Colorado, Denver
Alma College

Completed

Three New Ideas to Protect Special Forces From the Stress of High Altitude

Mountain Sickness

United States
Janssen-Cilag International NV

Completed

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia (PERFlexS)

Schizophrenia

France, United Kingdom, Belgium, Germany, Spain, Portugal, Bulgaria, Serbia, Switzerland, Israel, Finland, Greece, Sweden, Russian Federation, Netherlands, Denmark, Hungary, Lithuania, Latvia, Croatia, Turkey, Poland
University of North Carolina, Chapel Hill
National Institute of Mental Health (NIMH)

Terminated

The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood (Changes)

Stress, Emotional | Perimenopausal Disorder

United States
Danish Headache Center

Completed

Multiomics After Headache Provocation of People Who Are Unable to Have Headache

Healthy | Headache

Denmark
Daiichi Sankyo, Inc.

Completed

Baseline Epidemiologic Assessment of Abuse-Deterrence of MorphaBond Extended Release (BEAD-MB) (BEAD-MB)

Baseline Epidemiologic Assessment

United States
New York State Psychiatric Institute

Completed

An Open-Label Pilot Study of Sublocade as Treatment for Opiate Use Disorder

Opioid-use Disorder

United States
UConn Health
Yale University; Shire

Withdrawn

Guanfacine Extended Release and Mindfulness Skills Therapy

Stress Disorder

United States
Dr. Reddy's Laboratories Limited

Completed

A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules

Rosacea

Germany
Calo Psychiatric Center

Completed

Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment

Schizophrenics
Indivior Inc.

Completed

SUBLOCADE Rapid Initiation Extension Study

Opioid Use Disorder, Moderate | Opioid Use Disorder, Severe

United States
Columbia University
Veloxis Pharmaceuticals

Active, not recruiting

Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation

Renal Transplant Rejection | Kidney Transplant Failure and Rejection

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population

Pharmacokinetics

Mexico
Pfizer's Upjohn has merged with Mylan to form Viatris...

Terminated

A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks

Panic Disorder

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Terminated

A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder

Panic Disorder

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Terminated

A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder

Panic Disorder

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing Sites

Healthy Subjects

Singapore
University of Pennsylvania
Patient-Centered Outcomes Research Institute

Completed

Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone (OAPXRNTX)

Opiate Dependence

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder

Urinary Incontinence

United Kingdom

Search clinical trials for: Extended Release

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations